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Angiotensin II (Ang II) is associated with vascular hypertrophy, endothelial dysfunction and
activation of a number of inflammatory molecules, however the linear events involved
in the development of hypertension and endothelial dysfunction produced in response
to Ang II are not well defined. The goal of this study was to examine the dose- and
temporal-dependent development of endothelial dysfunction in response to Ang II. Blood
pressure and responses of carotid arteries were examined in control (C57Bl/6) mice and
in mice infused with 50, 100, 200, 400, or 1000 ng/kg/min Ang II for either 14 or 28
Days. Infusion of Ang II was associated with graded and marked increases in systolic
blood pressure and plasma Ang II concentrations. While low doses of Ang II (i.e., 50
and 100 ng/kg/min) had little to no effect on blood pressure or endothelial function, high
doses of Ang II (e.g., 1000 ng/kg/min) were associated with large increases in arterial
pressure and marked impairment of endothelial function. In contrast, intermediate doses
of Ang II (200 and 400 ng/kg/min) while initially having no effect on systolic blood pressure
were associated with significant increases in pressure over time. Despite increasing blood
pressure, 200 ng/kg/min had no effect on endothelial function, whereas 400 ng/kg/min
produced modest impairment on Day 14 and marked impairment of endothelial function
on Day 28. The degree of endothelial dysfunction produced by 400 and 1000ng/kg/min
Ang II was reflective of parallel increases in plasma IL-6 levels and vascular macrophage
content, suggesting that increases in arterial blood pressure precede the development of
endothelial dysfunction. These findings are important as they demonstrate that along with
increases in arterial pressure that increases in IL-6 and vascular macrophage accumulation
correlate with the impairment of endothelial function produced by Ang II.
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INTRODUCTION
It is well documented that angiotensin II (Ang II), the main
effector peptide of the renin-angiotensin system, produces hyper-
tension, oxidative stress, vascular hypertrophy, and endothelial
dysfunction (Bean et al., 1979; Brown et al., 1981; Didion et al.,
2002, 2005; Didion and Faraci, 2003; Cassis et al., 2004; Crowley
et al., 2005; Schrader et al., 2007). In humans, several forms of
hypertension are associated with increases in plasma Ang II levels,
such as renovascular hypertension and hypertension due to renin
secreting tumors (Catt et al., 1969, 1971; Garovic and Textor,
2005; Beevers et al., 2008). Genetic and experimental models,
such as mice which express human renin and angiotensinogen,
renovascular hypertension (e.g., 2-kidney, 1-clip) and infusion
of exogenous Ang II, are commonly used approaches to model
human hypertension associated with increases in Ang II (Bean
et al., 1979; Johns et al., 1996; Didion et al., 2000, 2002, 2005).
In the last couple of decades the use of Ang II infusion has
increased dramatically. It has been estimated that infusion of Ang
II is themost commonly usedmodel of hypertension as evidenced
by use in nearly half of all NIH grants involving the use of an
experimental model of hypertension (Galis et al., 2013). The pop-
ularity of the Ang II infusion model has been driven in part,
due to the ease of use, but also due to the advent of technolo-
gies associated with the generation of genetically-altered mice and
more recently genetically-altered rats (Smithies and Kim, 1994;
Geurts et al., 2009). The combination of the Ang II model and
genetic technologies has provided a wealth of information regard-
ing genes that contribute to the development of hypertension and
related vascular sequalae, including the role of oxidative stress and
inflammatory cytokines as well as inflammatory cell types in pro-
moting vascular hypertrophy and endothelial dysfunction (Bush
et al., 2000;Wang et al., 2001; Ryan et al., 2004; Didion et al., 2005,
2009; Guzik et al., 2007; Schrader et al., 2007; Madhur et al., 2010;
Barhoumi et al., 2011).
Recently, it has been suggested that there may be an overre-
liance on the Ang II model considering that the model is not
reflective of primary (essential) hypertension, which accounts for
the majority of hypertension in humans (Galis et al., 2013). While
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the Ang II infusion model is most reflective of secondary forms of
hypertension, it should be noted that a major target of antihy-
pertensive therapy in essential hypertension in humans has been
directed toward limiting Ang II signaling (e.g., ACE inhibitors and
angiotensin receptor blockers) (Sica, 2010; Hanselin et al., 2011).
Thus, the Ang II infusion model clearly has direct relevance to
human hypertension irrespective of etiology.
As with any model of human disease, there are both strengths
and limitations associated with the Ang II infusion model. For
example, Ang II infusion can produce immediate effects on blood
pressure, which is a strength of the model, but also a limitation,
as hypertension in humans usually develops over decades rather
than minutes or days. The use of high doses of Ang II, particularly
in the mouse, has been questioned as it relates to plasma con-
centrations observed in human hypertension. While is difficult
to extrapolate between studies in different species, any potential
comparison is complicated by the fact that in themajority of stud-
ies with Ang II infusion in mice either do not measure or do not
report plasma Ang II levels (Bush et al., 2000; Ryan et al., 2004;
Lee et al., 2006; Guzik et al., 2007; Didion et al., 2009; Barhoumi
et al., 2011). Another limitation is that it is often difficult to make
direct comparisons between studies, as there is marked variability
between studies in terms of the dose (anywhere from 490 up to as
high as 3600 ng/kg/min Ang II) and the length of time (as short as
3, 7, or 10 days and as long as 28 days) in which Ang II is infused
(Bean et al., 1979; Didion et al., 2005, 2009; Lee et al., 2006; Guzik
et al., 2007; Schrader et al., 2007; Madhur et al., 2010; Barhoumi
et al., 2011). This is also complicated by the fact that the major-
ity of studies in the literature examine single doses at single time
points thus providing limited insight into the temporal devel-
opment of hypertension and vascular dysfunction produced in
response to Ang II (Bush et al., 2000; Ryan et al., 2004; Lee et al.,
2006; Guzik et al., 2007; Didion et al., 2009; Barhoumi et al.,
2011).
We had several goals for the present study. First, we sought to
determine the effects of Ang II on blood pressure and plasma
Ang II levels. Second, we sought to determine whether hyper-
tension per se promoted the impairment of endothelial function
or vice versa. Finally, we sought to determine the sequential and
temporal activation of inflammatory molecules in the develop-
ment of endothelial dysfunction in response to Ang II.We focused
our studies of vascular function to the carotid artery, as carotid
artery disease and hypertension are both important risk factors
for ischemic stroke (Go et al., 2013; Kernan et al., 2014).
METHODS
ANIMALS
Male C57Bl/6 mice (#000664; n = 46) were obtained from
the Jackson Laboratory (Bar Harbor, ME) and were randomly
selected to either one of two groups (i.e., control or Ang II-
infused group). Mice selected to the Ang II-infused group
were implanted with either a 14 Day (Alzet® Model 1002;
DURECT™ Corporation, Cupertino, CA) or a 28 Day (Alzet®
Model 1004) micro-osmotic pump containing 50, 100, 200, 400,
or 1000 ng/kg/min Ang II as described previously (Didion et al.,
2005; Schrader et al., 2007). All experimental protocols conform
to the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use
Committee at the University of Mississippi Medical Center.
SYSTOLIC BLOOD PRESSURE MEASUREMENTS
Systolic blood pressure was measured using tail-cuff plethysmog-
raphy (Visitech Systems BP-2000 Series II Blood Pressure Analysis
System™, Apex, NC) in a manner similar to that described previ-
ously by our laboratory (Didion et al., 2005; Schrader et al., 2007).
Briefly, mice were trained for a period of 5 consecutive days in
which blood pressure was measured (30 measurements per day)
but not recorded. Following this training period, blood pressure
was measured for another 3 consecutive days, recorded and aver-
aged. The blood pressure measured during this period is reported
as baseline (Day 0). Blood pressure was then measured on Days 3,
7, 14, 21, and 28 in both control and Ang II-infused groups.
STUDIES OF ENDOTHELIAL FUNCTION IN CAROTID ARTERY
Depending on whether mice were implanted with a 14 or 28
Dayminipump they and their respective controls were euthanized
on either Day 14 or 28 with pentobarbital sodium (150mg/kg
ip). Arterial blood was collected for measurements of plasma
Ang II and IL-6 levels. Bestatin® (Sigma Chemical, St Louis,
MO) was added to the blood samples in order prevent proteol-
ysis of angiotensinogens. Both common carotid arteries as well
as the thoracic aorta were carefully dissected and removed for
studies of endothelial function as well as measurement of vascu-
lar macrophage content and medial cross-sectional area (CSA),
respectively.
For studies of endothelial function, carotid arteries were
placed in Kreb’s buffer with the following composition (mmol/L):
NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25, glucose 11. Loose connective tissue was removed
and then each carotid artery was cut into two vascular
rings each 3–4mm in length. Vascular rings were connected
to a force transducer to measure isometric tension (con-
traction and relaxation) in individual organ baths contain-
ing 20ml Krebs buffer maintained at 37◦C and gassed with
a mixture of 95% O2 and 5% CO2. Following a 45-min
equilibration period vessels were pre-contracted (50–60% of
maximum) with the thromboxane analog, 9,11-dideoxy-11a-
epoxymethanprotaglandin F2α (U46619). After achieving a sta-
ble contraction plateau, concentration-response curves were
generated to acetylcholine (an endothelium-dependent ago-
nist; 0.01–100μmol/L) and to nitroprusside (an endothelium-
independent agonist; 0.01–100μmol/L). Concentration-response
curves were recorded using PowerLab® data acquisition systems
and analyzed off-line with LabChart® software (ADInstruments,
Colorado Springs, CO).
MEASUREMENT OF VASCULAR HYPERTROPHY
For measurements of medial CSA aortas were fixed in 4%
buffered paraformaldhyde and then processed and embedded in
paraffin while maintaining vessels in a cross-sectional orienta-
tion. Aortas were sectioned (7 microns), placed on microscope
slides, stained with hematoxalin and eosin and then cover slipped.
Sections were viewed and imaged using a Nikon Eclipse Ni-U
microscope. Medial CSA of the carotid artery was determined
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using Nikon NIS-Elements software as described previously
(Schrader et al., 2007).
MEASUREMENT OF PLASMA ANG II AND IL-6 LEVELS
Plasma levels of Ang II and IL-6 were measured using a high-
sensitivity mouse Ang II (Enzo, New York, NY) and IL-6 (R&D
Biosciences, Minneapolis, MN) ELISA kit, respectively, according
to manufacturer’s instructions.
MEASUREMENT OF VASCULAR MACROPHAGES
For measurement of vascular macrophage content, anterior seg-
ments of the left common carotid artery were frozen in optimal
cutting temperature (O.C.T., Tissue-Tek, Sakura Finetek, USA)
compound. Carotid arteries were sectioned using a cryostat and
placed on glass microscope slides, boiled for 20min in 10mM
citrate buffer, and blocked in 5% goat serum for 1 h at room
temperature. Slides were incubated with a general macrophage
(CD68) primary antibody (Abcam, ab955) overnight at 4◦C.
Prior to the horseradish peroxidase conjugated secondary anti-
body incubation slides were treated with 0.3% hydrogen peroxide
followed by incubation with 3,3′-diaminobenzidine (DAB) for
10min. Slides were counterstained with hematoxylin and CD68
positive cells were examined and counted (at a magnification
of 40x) using light microscopy (Nikon Eclipse Ni microscope,
Tokyo, Japan).
DRUGS
Acetylcholine, Ang II (human, acetate salt), and nitroprusside
were obtained from Sigma (St. Louis, MO) and were dissolved
in saline. U46619 (in methyl acetate) was obtained from Cayman
Chemical (Ann Arbor, MI) and evaporated with 100% nitrogen
gas and re-suspended in 100% ethanol with subsequent dilu-
tions being made with saline. All other reagents were of standard
laboratory grade.
STATISTICAL ANALYSIS
All data are expressed as Means ± SE. Comparisons of blood
pressure were made using Two-Way ANOVA. Responses to acetyl-
choline and nitroprusside are expressed as a percent relaxation to
U46619-induced contraction and were compared using Two-Way
ANOVA for repeated measures followed by Bonferroni post-hoc
test. Medial cross-sectional area, plasma Ang II and IL-6 concen-
tration, as well as vascular macrophage content were compared
using One-Way ANOVA. Statistical significance was accepted at
P < 0.05.
RESULTS
ANG II INFUSION IS ASSOCIATED WITH DOSE-DEPENDENT
INCREASES IN BLOOD PRESSURE
Baseline systolic blood pressure was similar (P > 0.05) in all
groups of mice prior to infusion of Ang II (Day 0) and collectively
averaged 116 ± 5mmHg. Ang II infusion was associated with a
graded pressor response that was dependent on both the dose and
length of time of Ang II infusion (Figure 1). For example, infu-
sion of either 50 or 100 ng/kg/min Ang II had no effect (P > 0.05)
on systolic blood pressure. Blood pressure in mice infused with 50
and 100 ng/kg/min was similar to that in control mice on Days 14
and 28. Infusion of 200 ng/kg/min Ang II was associated with a
FIGURE 1 | Ang II infusion produces dose-dependent increases in
systolic blood pressure. (A) Systolic blood pressure over the course of 28
days in control and Ang II-infused mice as measured using tail-cuff
plethysmography. (B) Delta change in blood pressure on Day 28 in
response to graded doses of Ang II. Means ± SE; n = 3–8/group;
∗P < 0.05 vs. Control; #P < 0.05 vs. 1000 ng/kg/min.
gradual increase in systolic pressure, which began by Day 14 and
reached a maximum of 134 ± 2mmHg on Day 28. Infusion of
400 ng/kg/min Ang II was also associated with a gradual increase
in blood pressure that began on Day 7 reaching a maximum of
150± 3mmHg onDay 28 (Figure 1). In contrast, Infusion of Ang
II at a rate of 1000 ng/kg/min was associated with a marked and
immediate increase in blood pressure (136 ± 6mmHg on Day 3)
that was maintained throughout the infusion period reaching a
maximum of 158 ± 6mmHg on Day 28.
ANG II INFUSION IS ASSOCIATED WITH DOSE-DEPENDENT
INCREASES IN PLASMA ANG II LEVELS
Ang II levels in control mice were 49 ± 12 pg/ml (Figure 2). In
mice infused with 50 and 100 ng/kg/min Ang II, plasma Ang II
levels were similar (P > 0.05) to that in control mice and averaged
63 ± 12 and 112 ± 7 pg/ml, respectively. Infusion of 200, 400,
and 1000 ng/kg/min Ang II was associated with dose-dependent
increases in plasma Ang II (Figure 2). For example, plasma Ang II
levels in mice infused with 200 and 400 ng/kg/min were 173 ± 56
and 237 ± 46 pg/ml, respectively and were significantly different
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FIGURE 2 | Systolic blood pressure is positively associated with
plasma Ang II levels. (A) Plasma Ang II levels as measured by ELISA on
Day 28. (B) Plasma Ang II concentration-blood pressure response curve
(R2 = 0.8206). Means ± SE; n = 3–8/group; ∗P < 0.05 vs. Control.
(P < 0.05) from Ang II levels in control mice but were not differ-
ent (P > 0.05) from each other. Infusion of 1000 ng/kg/min Ang
II was associated with the greatest increase in plasma Ang II levels
(i.e., 456 ± 106 pg/ml), which was significantly higher than that
in either control mice or any of the other Ang II-infused groups
(Figure 2). When plasma Ang II levels were plotted against blood
pressure, we found that there was a strong correlation between
plasma Ang II levels and systolic blood pressure (Figure 2).
ANG II INFUSION IS ASSOCIATED WITH DOSE- AND TIME-DEPENDENT
REDUCTIONS IN ENDOTHELIAL FUNCTION
In carotid arteries from control mice, acetylcholine produced
concentration-dependent relaxation that was similar on Day 14 as
that observed on Day 28 (Figures 3, 4). For example, 100μmol/L
acetylcholine produced 95 ± 3 and 97 ± 2% relaxation in
carotid arteries from control mice on Day 14 and 28 respectively.
Acetylcholine also produced relaxation in mice infused with 50
or 100 ng/kg/min of Ang II that was similar (P > 0.05) to that in
control mice both onDay 28 (Figure 3). For example, 100μmol/L
acetylcholine produced 89 ± 7% relaxation in mice infused with
50 ng/kg/min Ang II and 100 ± 4% relaxation in mice infused
with 100 ng/kg/min Ang II on Day 28.
FIGURE 3 | (A) Endothelium-dependent responses to acetylcholine (Ach)
and (B) Endothelium–independent responses to nitroprusside (SNP) in
carotid arteries from control mice and mice infused with 50 or
100 ng/kg/min of Ang II for 28 days. Means ± SE; n = 3/group; P > 0.05.
In contrast, Ang II was associated with endothelial dysfunction
inmice infused with 200, 400, and 1000 ng/kg/min Ang II that was
dependent on both the dose and length of time of Ang II infusion
(Figure 4). For example, 200 ng/kg/min Ang II was associated
with a small rightward shift in the concentration-response curve
to acetylcholine. However, 200 ng/kg/min Ang II had no effect
(P > 0.05) on the relaxation produced by the highest concentra-
tion of acetylcholine (e.g., 100mmol/L acetylcholine produced 89
± 2 and 81 ± 4% relaxation on Day 14 and 28, respectively, in
carotid arteries from mice infused with 200 ng/kg/min).
Similarly, relaxation to acetylcholine in carotid arteries from
mice infused with 400 ng/kg/min Ang II was associated with a
moderate degree of impairment of endothelial function on Day
14, however with time the degree of impairment was signifi-
cantly greater (P < 0.05) on Day 28 (Figure 4). For example,
100μmol/L acetylcholine produced 80 ± 6 and 55 ± 6% relax-
ation in carotid artery frommice infused with 400 ng/kg/min Ang
II for 14 and 28 days, respectively.
Finally, 1000 ng/kg/min Ang II was associated with marked
impairment of endothelial function in response to acetylcholine
by Day 14 and was similar to that with infusion of 1000 ng/kg/min
Ang II for 28 Days (Figure 4). For example, 1000 ng/kg/min Ang
II was associated with 56 ± 7 and 58 ± 6% relaxation on Day
14 and 28, respectively. Endothelium-independent responses to
nitroprusside were normal in control mice and mice infused
with 50, 100, and 200 ng/kg/min, however responses to nitro-
prusside in carotid arteries from mice infused with 400 and
1000 ng/kg/min were significantly reduced as compared to those
in control mice (data not shown).
ANG II INFUSION WAS ASSOCIATED WITH VASCULAR HYPERTROPHY
Ang II was associated with vascular hypertrophy only with
infusion of 200, 400, and 1000 ng/kg/min Ang II (Figure 5).
Surprisingly, the effect of Ang II was for themost part all-or-none,
with low doses of Ang II (i.e., 50 and 100 ng/kg/min) having no
effect onmedial CSA, whereas 200, 400, and 1000 ng/kg/min were
all associated with significant increases in medial CSA. The degree
of hypertrophy produced by all three doses was of similar mag-
nitude and appeared to occur by Day 14 and did not appear to
increase any further at Day 28 (Figure 5).
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FIGURE 4 | Ang II produces impairment of endothelial function
in a dose- and time-dependent manner. Responses to
acetylcholine (Ach) in carotid arteries from control mice and mice
infused with 200 ng/kg/min, 400 ng/kg/min, or 1000 ng/kg/min of Ang
II for 14 or 28 days. Means ± SE; n = 6–8/group; ∗P < 0.05 vs.
Control; #P < 0.05 vs. Day 28.
FIGURE 5 | Medial cross-sectional area (aortic) on (A) Day 14 and (B)
Day 28 in control and Ang II infused mice. Means ± SE; n = 3–6/group;
∗P < 0.05 vs. Control.
ANG II INFUSIONWAS ASSOCIATED WITH INCREASES IN PLASMA
IL-6 LEVELS AND VASCULAR MACROPHAGE CONTENT
Plasma IL-6 levels were relatively low in control mice as would
be predicted in the absence of inflammation and averaged 4 ± 3
pg/ml (Figure 6). Infusion of 200, 400, and 1000 ng/kg/min Ang
FIGURE 6 | Ang II infusion is associated with dose- and
time-dependent increases in plasma IL-6. Plasma IL-6 levels in control
and Ang II infused mice on (A) Day 14 and (B) Day 28 as determined by
ELISA. Means ± SE; n = 3–6/group; ∗p < 0.05 vs. Control.
II for 14 Days was associated with 6-, 8-, and 16-fold higher levels
of IL-6 than that in control mice, e.g., IL-6 levels in mice infused
with 200, 400, and 1000 ng/kg/min Ang II averaged 22 ± 4, 29 ±
8, and 64 ± 11 pg/ml, respectively (Figure 6).
Infusion of 50, 100, 200, 400, and 1000 ng/kg/min Ang II for 28
Days was associated with plasma IL-6 levels that averaged 6 ± 6,
10 ± 10, 15 ± 6, 58 ± 19, and 64 ± 18 pg/ml, respectively. While
plasma IL-6 levels in mice infused 50, 100, and 200 ng/kg/min
were not different (P > 0.05) from that in control mice, infusion
of 400 and 1000 ng/kg/min were significantly greater than that
in control mice. More importantly, plasma IL-6 levels with infu-
sion of 400 ng/kg/min Ang II for 28 Days was significantly greater
(P < 0.05) than that with 14-Day infusion. Plasma IL-6 levels in
mice infused with 1000 ng/kg/min Ang II for 28 Days were not
different (P > 0.05) than that with infusion 1000 ng/kg/min Ang
II for 14 Days (Figure 6). Interestingly, the number of vascular
macrophages was significantly higher in mice infused with 400
and 1000 ng/kg/min Ang II as compared to that in control mice
andmice infused with 200 ng/kg/min (Figure 7). Finally, when we
examined the relationship between plasma IL-6 levels and plasma
Ang II and systolic blood pressure we found that there was a
strong correlation between the two (Figure 8). In contrast, there
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FIGURE 7 | (A) Representative micrographs of vascular macrophage
content in carotid arteries from control and Ang II infused (200, 400,
and 1000 ng/kg/min) mice. (B) Quantification of vascular macrophage
accumulation in carotid arteries from Control and Ang II-infused mice.
Magnification: 40x; Scale bar = 500μm. n = 3/group; ∗p < 0.05 vs.
control.
FIGURE 8 | (A,B) While there is a direct correlation between plasma Ang II
levels and plasma IL-6 and between plasma IL-6 levels and systolic blood
pressure there was (C) an inverse relationship between plasma IL-6 and
endothelial responses to acetylcholine (Ach) following Ang II infusion.
was a strong negative relationship between plasma IL-6 levels and
the degree of endothelial function (Figure 8).
DISCUSSION
There are several important findings of the present study. First,
Ang II over a wide range of doses in the mouse was associ-
ated with increases in systolic blood pressure that displayed both
dose and time dependency. Second, the effective steady-state
plasma concentration of Ang II that was required to produce
a pressor response was ≥170 pg/ml, which was achievable with
infusion of doses of Ang II greater than 200 ng/kg/min. Third,
Ang II infusion was associated with minimal to no impairment
of endothelial function at low doses (50–200 ng/kg/min) and
marked impairment (nearly 50%) at the highest dose of Ang
II (1000 ng/kg/min). Most interestingly, infusion of Ang II at
400 ng/kg/min was the only dose of Ang II that was associated
with a temporal impairment of endothelial function. Fourth,
plasma IL-6 levels and perivascular macrophage accumulation
increased in parallel with blood pressure and plasma Ang II
levels. More importantly, impairment of endothelial function
was found to correlate directly with IL-6 levels and macrophage
accumulation.
DOSE AND TEMPORAL EFFECTS OF ANG II INFUSION ON BLOOD
PRESSURE AND PLASMA ANG II LEVELS
While there is a fair amount of information regarding the effects
of infusion of high doses of Ang II (e.g., 400–3600 ng/kg/min)
(Kawada et al., 2002; Didion et al., 2005, 2009; Gavazzi et al., 2006;
Lee et al., 2006; Guzik et al., 2007; Barhoumi et al., 2011), there is
little to no information regarding the effects of lower doses (i.e.,
<400 ng/kg/min) on arterial pressure in themouse. In the present
study, we found that infusion of either 50 or 100 ng/kg/min Ang II
was not associated with alterations in systolic blood pressure up to
and including Day 28. The lack of effect of 50 and 100 ng/kg/min
Ang II on blood pressure could be explained by fact that these
doses were not associated with increases in plasma Ang II levels.
In contrast to the effects of lower doses, we found that infu-
sion of intermediate doses of Ang II were associated with biphasic
blood pressure responses. For example, 200 ng/kg/min had no
effect on blood pressure up to Day 13, however blood pressure
began to increase on Day 14 and by Days 21 and 28 blood pressure
was significantly higher than baseline levels by at least 20mmHg.
Similarly, infusion of 400 ng/kg/min Ang II also produced a
biphasic response, however the pressor response occurred earlier
(by at least Day 7) and was of greater magnitude (∼10mmHg
greater than that produced by 200 ng/kg/min). Our data with
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200 and 400 ng/kg/min Ang II are consistent with previous find-
ings using similar doses for shorter periods of time (<14 Days)
(Kawada et al., 2002; Didion et al., 2009). Our findings also
provide new information regarding long-term effects of Ang II
infusion up to and including 28 Days.
Plasma Ang II levels were significantly higher in mice infused
with 200 and 400 ng/kg/min Ang II compared to control mice,
suggesting that these doses were sufficient to increase plasma Ang
II concentrations and activate AT1 receptors. Our findings also
suggest that there is a threshold of plasma Ang II of at least
170 pg/ml Ang II in order for Ang II to have any significant effect
on blood pressure. While plasma Ang II levels tended to be higher
in mice infused with 400 ng/kg/min they were not significantly
different than those in mice infused with 200 ng/kg/min Ang II.
It is difficult to know how such small incremental differences
in plasma Ang II could have such differential effects on blood
pressure, however one possibility may involve compartmentalized
formation of endogenous Ang II in response to exogenous Ang II
infusion. Indeed, Ang II infusion has been shown to stimulate de
novo generation of intrarenal Ang II, which has been suggested
to contribute to slow pressor response produced by low-dose Ang
II infusion and may in part account for the differences in blood
pressure produced by 200 and 400 ng/kg/min Ang II in the present
study (Navar et al., 2011).
Infusion of 1000 ng/kg/min Ang II was associated with an
immediate (by Day 3) increase in systolic blood pressure of nearly
40mmHg, which was maintained throughout the 28-day infu-
sion period. This is consistent with previous studies, including
our own, in which 1000 ng/kg/min is typically associated with
increases in arterial pressure of 40–50mmHg (Didion et al., 2005;
Schrader et al., 2007). In addition, the increase in arterial pres-
sure achieved with 1000 ng/kg/min Ang II appears to represent an
upper limit to which blood pressure can be increased with Ang II
as infusion of higher doses (e.g., 3600 ng/kg/min) have not been
found to increase blood pressure to any greater extent than that
achieved with 1000 ng/kg/min (Lee et al., 2006).
As one might predict, infusion of 1000 ng/kg/min Ang II was
associated with the largest increase in plasma Ang II levels (nearly
450 pg/ml). While we did not measure plasma Ang II levels other
than on Day 28 we would suggest that the levels of Ang II mea-
sured on Day 28 most likely represents plasma steady-state levels
that are achieved with long-term infusion of Ang II. Surprisingly,
the majority of studies using the Ang II infusion model in mice
do not measure and/or report plasma Ang II levels (Bush et al.,
2000; Crowley et al., 2005, 2006; Didion et al., 2005; Lee et al.,
2006; Guzik et al., 2007; Madhur et al., 2010; Barhoumi et al.,
2011). In the present study, we measured plasma Ang II lev-
els in all our experimental groups and found that there was
a direct correlation between plasma Ang II levels and arterial
pressure consistent with observations in other species, includ-
ing man (Chinn and Dusterdieck, 1972; Bean et al., 1979; Brown
et al., 1981; Cholewa and Mattson, 2001; Beevers et al., 2008).
The present study is the first to our knowledge to characterize
the plasma Ang II concentration-blood pressure response curve
following subcutaneous infusion of Ang II in the mouse.
Previous studies have shown that the increase in blood pres-
sure produced by Ang II is mediated in large part by increases
in oxidative stress, as scavengers of oxidative stress such as
Tempol limit the increase in pressure produced by Ang II infu-
sion (Kawada et al., 2002). The initial increase in blood pressure in
response to high pressor doses of Ang II appears to bemediated by
Nox2-derived superoxide (Wang et al., 2006). In contrast, Nox1-
derived superoxide appears to mediate the long-term effects of
Ang II on blood pressure as Nox1 deficiency is associated with a
rapid increase in blood pressure followed by a return toward base-
line levels (Matsuno et al., 2005; Gavazzi et al., 2006). Although
we did not examine the role of oxidative stress in the develop-
ment of hypertension in present study, we would speculate that
both Nox1- and Nox2-derived superoxide contribute to indepen-
dent phases of the hypertension produced in response to Ang II
and aremediated via combined and/or temporal activation of vas-
cular, central, as well as renal AT1 receptors (Zimmerman et al.,
2002; Ryan et al., 2004; Crowley et al., 2005, 2006).
DOSE AND TEMPORAL EFFECTS OF ANG II ON PLASMA IL-6 LEVELS
AND VASCULAR FUNCTION AND MACROPHAGE ACCUMULATION
In addition to hypertension, Ang II can produce endothelial dys-
function in a number of blood vessels (e.g., aorta, carotid artery,
cerebral arterioles) in several species, including mice (Rajagoplan
et al., 1996; Su et al., 1998; Didion et al., 2000, 2002, 2005;
Wang et al., 2001; Didion and Faraci, 2003; Faraci et al., 2006;
Guzik et al., 2007; Barhoumi et al., 2011). Both pharmacologi-
cal and genetic approaches have demonstrated that NO (derived
primarily from eNOS) is a major mediator of endothelium-
dependent relaxation in mouse carotid artery (Faraci et al., 1998).
Oxidative stress, such as increases in vascular superoxide levels,
limits NO bioavailability and endothelium-dependent relaxation
(Didion et al., 2005). We, and others, have shown that interven-
tions directed at reducing vascular superoxide levels produced in
response to a number of stimuli, including Ang II, are very effec-
tive in restoring NO and improving endothelial function (Didion
and Faraci, 2002, 2005; Didion et al., 2005). Additionally, we have
shown that the endothelial dysfunction produced in response to
Ang II is mediated primarily through AT1 receptors (Ryan et al.,
2004).
High doses of Ang II (i.e., ≥ 490 ng/kg/min) produce marked
impairment of endothelial function (Bean et al., 1979; Didion
et al., 2005, 2009; Guzik et al., 2007; Schrader et al., 2007;
Madhur et al., 2010; Barhoumi et al., 2011), however the effects
of lower doses of Ang II on vascular function and structure are
poorly defined. Thus, in order to elucidate the temporal pro-
cesses involved in the development of vascular hypertrophy and
endothelial dysfunction in response to Ang II, we examined the
effect of multiple doses and time points of Ang II infusion on
both of these processes. We elected to examine vascular function
in carotid artery, as endothelial dysfunction in this blood vessel is
major risk factor for ischemic stroke (Roger et al., 2012; Kernan
et al., 2014).
In the present study, we found that, like blood pressure, the
degree of endothelial dysfunction produced by Ang II was both
dose- and time-dependent. For example, low doses of Ang II (e.g.,
50 and 100 ng/kg/min Ang II), which did not effect on blood
pressure, were also without effect on endothelial function and
vascular structure. The lack of effect of these two doses is most
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likely reflective of the fact that they were not associated with
increases in plasma Ang II levels and thus not sufficient to activate
AT1 receptor signaling. Similarly, doses of Ang II that were asso-
ciated with slowly developing increases in arterial pressure and
plasma Ang II levels (such as 200 ng/kg/min Ang II) were sur-
prisingly not associated with alterations in endothelial function
despite a marked increase in vascular hypertrophy. Interestingly,
infusion of 200 ng/kg/min Ang II was not associated with alter-
ations in plasma IL-6 levels or vascular macrophage content
compared with that in control mice, suggesting that the increase
in blood pressure at these doses occurs independently of increases
in inflammatory cells and cytokines. Additionally, our data with
200 ng/kg/min Ang II also suggest that vascular hypertrophy pre-
cedes the development of hypertension, consistent with the idea
that the effect of non-pressor doses of Ang II on vascular structure
are due to direct effects of Ang II and independent of blood pres-
sure (Owens and Schwartz, 1982; Berk et al., 1989; Griffin et al.,
1991; Su et al., 1998).
Perhaps of equal importance, we found that infusion of
400 ng/kg/min Ang II was the only dose in the present study that
was associated with temporal impairment of endothelial func-
tion. Ang II at this dose was associated with minimal impairment
of endothelial function as evidenced by the reduced response
to acetylcholine at Day 14. However, endothelial function was
impaired to a much greater extent (i.e., a reduction of approxi-
mately 50% in the response to acetylcholine) on Day 28 in mice
that were infused 400 ng/kg/min Ang II. The degree of impair-
ment associated with 28-day infusion of 400 ng/kg/min Ang II
was very similar to the degree of endothelial dysfunction pro-
duced with either 14 or 28 day infusion of 1000 ng/kg/min Ang II,
both of which were associated with increases in IL-6 and vascu-
lar macrophage levels. Taken together, these findings suggest that
inflammation is a major contributor to endothelial dysfunction
produced in response to Ang II and is most likely reflective of the
degree of hypertension produced by Ang II and/or the length of
time hypertension is present.
Consistent with previous studies, infusion of 1000 ng/kg/min
of Ang II produced approximately 50% impairment of
endothelium-dependent relaxation in response to acetyl-
choline as early as Day 14 (Didion et al., 2005; Schrader et al.,
2007). The degree of impairment produced by 1000 ng/kg/min
was not affected by the length of time in which Ang II was infused
as it was found to be similar on Day 28 as that observed on
Day 14. Ang II is known to increase levels of proinflammatory
cytokines, such as IL-6, IL-17, and IL-18, in vascular cells (Faraci
et al., 1998; Funakoshi et al., 1999; Han et al., 1999; Liu et al.,
2003; Sahar et al., 2005; Schrader et al., 2007; Johnson et al.,
2013). Consistent with this concept, we found in the present
study that IL-6 levels were nearly 60-fold higher in mice infused
with 1000 ng/kg/min Ang II than that in control mice. Moreover,
the increase in plasma IL-6 correlated directly with the degree of
endothelial dysfunction and vascular macrophage content.
Functional effects of Ang II-induced increases in IL-6 includes
downstream activation of STAT3 (Schieffer et al., 2000; Johnson
et al., 2013). STAT3 activation has been shown to have a num-
ber of effects, including inhibition of eNOS promoter activity and
reductions in eNOS gene expression (Saura et al., 2006), thereby
providing a mechanistic link by which IL-6 serves to produce
endothelial dysfunction. IL-6 has also been shown to increase
expression of AT1 receptors in vascular muscle, which would
serve to promote Ang II signaling including increased NFκB acti-
vation and IL-6 gene transcription (Han et al., 1999), which
would then further enhance IL-6 mediated-reductions in eNOS
expression and promote increases in oxidative stress (Wassmann
et al., 2004). While we did not examine the contribution of oxida-
tive stress to the impairment of endothelial function, previous
studies, including our own, have shown that increases in oxida-
tive stress, particularly Nox2-derived superoxide, contribute to
endothelial dysfunction produced by Ang II (Rajagoplan et al.,
1996; Didion et al., 2005, 2009; Schrader et al., 2007). While it is
difficult to differentiate whether vascular or infiltrating immune
cells (as evidence by the increase in vascular macrophage con-
tent) associated with 400 and 1000 ng/kg/min Ang II) contributed
to the increase in plasma IL-6 which then serves to promote
increases in oxidative stress, we have shown previously that vas-
cular IL-6 expression contributes to Ang II-induced impairment
of endothelial responses (Schrader et al., 2007).
In conclusion, the findings from our study provide a com-
prehensive examination of the effects of Ang II on both blood
pressure and endothelial function in the mouse. Our findings
demonstrate that Ang II produces hypertension and endothe-
lial dysfunction in a dose- and time-dependent manner. These
findings are important as they serve to delienate the tempo-
ral events associated with the development of Ang II-induced
endothelial dysfunction. Our data also demonstrate along with
increases in arterial pressure that there is a strong correlation
between increases in IL-6 and vascular macrophage accumulation
and the degree of endothelial dysfunction produced by Ang II. It
will be important to determine whether inflammation promotes
oxidative stress or vice versa and whether targeting one or both
pathways will be most effective in limiting the negative effects
of Ang II on vascular function in human hypertension. This is
especially important considering that plasma IL-6 correlates with
negative cardiovascular outcomes in humans (Ikeda et al., 1992;
Ridker et al., 2000a,b).
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